Roche turns up the heat on Lilly with another Gavreto approval, elbowing its way into the thyroid cancer space
Roche and Blueprint Medicines are continuing to put pressure on rivals Eli Lilly and Loxo, as their Gavreto drug picked up a new approval Wednesday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
